ARTL - Artelo Biosciences on go with cancer appetite recovery study

The Medicines and Healthcare products Regulatory Agency ((MHRA)) has signed-off the Phase 1/2 trial in the U.K. evaluating Artelo Biosciences' ([[ARTL]] +5.7%) ART27.13, synthetic cannabinoid, in patients with cancer anorexia and weight loss. Enrollment expected to initiate before year end.ART27.13 is a highly potent, peripherally restricted synthetic, dual G protein-coupled receptor agonist believed to target peripheral CB1/CB2 receptors, which has the potential to increase appetite and food intake.

For further details see:

Artelo Biosciences on go with cancer appetite recovery study